Sanofi to Present New Clinical Data, Including Results From the Investigational New Insulin U300, at the American Diabetes Association 73rd Scientific
AsiaNet 53430
Sanofi to Present New Clinical Data, Including Results From the Investigational New Insulin U300, at the American Diabetes Association 73rd Scientific Sessions
PARIS, June 18/PRN=KYODO JBN/ --
Sanofi (EURONEXT : SAN and NYSE : SNY) announced today that clinical data
highlighting the company's ongoing commitment to advancing diabetes care will
be presented at the American Diabetes Association (ADA) 73rd Scientific
Sessions in Chicago, USA (June 21 - 25, 2013). In total, more than 60
abstracts representing new data sets on Sanofi diabetes drugs, investigational
drugs or medical devices are part of the official scientific program.
"The American Diabetes Association annual meeting provides an important
opportunity for Sanofi to share significant data with the medical community and
to demonstrate our focus on advancing scientific thinking in the field of
diabetes treatment," said Pierre Chancel, Senior Vice President, Global
Diabetes at Sanofi. "The data being presented further support the company's
leadership in integrated diabetes care and delivering personalized solutions
that directly target the needs of people living with this disease."
Among the study findings being presented in poster and oral scientific
sessions are the following (abstracts have been posted on the ADA website):
Investigational new insulin U300
The EDITION I study compared the efficacy and safety of investigational new
insulin U300 vs. Lantus(R) (insulin glargine) in people with type 2 diabetes
using basal plus mealtime insulin. The EDITION I study is part of a larger
Phase III clinical program.
"New insulin glargine formulation: glucose control and hypoglycemia in
people with type 2 diabetes using basal and mealtime insulin (EDITION I)"
Embargo lifts: Saturday, June 22, 10 am CST
Presenter: M. Riddle, Oregon Health and Science University,
Portland,
USA
Location: Poster Hall
The pharmacodynamic and pharmacokinetic properties of the investigational
new insulin U300 were examined in a double-blind, randomized study in patients
with type 1 diabetes:
"Euglycemic clamp profile of new insulin glargine U300 formulation in
patients with type 1 diabetes (T1DM) is different from glargine U100"
Embargo lifts: Saturday, June 22, 10 am CST
Presenter: R. Dahmen, Sanofi, Frankfurt am Main, Germany
Location: Poster Hall (also available as an ePoster on the ADA
website
after 10 am, June 22)
"New insulin glargine U300 formulation evens and prolongs steady state PK
and PD profiles during euglycemic clamp in patients with type 1 diabetes (T1DM)"
Embargo lifts: Saturday, June 22, 1:45 pm CST
Presenter: T. Jax, Profil, Neuss, Germany
Location: W-375A
Lyxumia(R) (lixisenatide)*
Lyxumia(R), the first once-daily prandial GLP-1 receptor agonist, is
approved in the European Union for the treatment of adults with type 2 diabetes
mellitus to achieve glycemic control in combination with oral glucose-lowering
medicinal products and/or basal insulin when these, together with diet and
exercise, do not provide adequate glycemic control.
Lyxumia(R) data include two analyses investigating its post-prandial
mechanism of action:
"Once-daily lixisenatide as add-on to basal insulin plus or minus OADs in
patients with type 2 diabetes selectively reduces postprandial hyperglycemic
daytime exposure"
Embargo lifts: Saturday, June 22, 10 am CST
Presenter: M. Riddle, Oregon Health and Science University, Portland,
USA
Location: Poster Hall (also available as an ePoster on the ADA
website after 10 am, June 22)
"Efficacy of lixisenatide in the GetGoal clinical trial program: pooled
analysis of postprandial metabolic outcomes"
B. Ahren, Lund University, Sweden. Abstract publication only.
Further data include analyses of the effects of Lyxumia(R) in combination
with basal insulin on HbA1c, weight gain and symptomatic hypoglycemia in
patients with type 2 diabetes:
"Expanding the basal-plus regimen: basal insulin + lixisenatide is more
likely to achieve the composite outcome of HbA1c ＜7%, no documented symptomatic
hypoglycemia and no weight gain compared with basal + prandial insulin"
Embargo lifts: Saturday, June 22, 10 am CST
Presenter: J. Rosenstock, Dallas Diabetes & Endocrine Center, Texas,
USA
Location: Poster Hall (also available as an ePoster on the ADA
website after 10 am, June 22)
"Meta-analysis of randomized controlled trials of lixisenatide as add-on to
basal insulin in patients with type 2 diabetes mellitus"
Embargo lifts: Saturday, June 22, 10 am CST
Presenter: B. Charbonnel, University of Nantes, France
Location: Poster Hall (also available as an ePoster on the ADA
website after 10 am, June 22)
ORIGIN (Outcome Reduction with Initial Glargine INtervention)[1]
ORIGIN is a unique, seven-year landmark cardiovascular (CV) outcomes trial,
evaluating Lantus(R) vs. standard care in over 12,500 individuals who are at
high CV risk with pre-diabetes or early type 2 diabetes mellitus. Spanning 40
countries worldwide, it is the world's longest and largest randomized clinical
trial of its type in this population, and the first to formally evaluate the
effects of insulin on CV outcomes.
Results from a new sub-analysis of ORIGIN will be presented:
"Cancer outcomes in patients with dysglycemia on basal insulin: results of
the ORIGIN trial"
Embargo lifts: Monday, June 24, 8 am CST
Presenter: LJ. Bordeleau, McMaster University, Ontario, Canada
Location: S-103B
ATLAS (Asian Treat to Target Lantus(R) Study)
The ATLAS study compared the effectiveness of a patient-led vs.
physician-led initiation of Lantus(R) in 552 patients with type 2 diabetes in
Asia and Russia. Due to the specific challenges faced by people living with
diabetes in Asia, this study investigated whether self-adjustment of insulin in
this population is similarly effective at lowering blood glucose levels as it
is in Western diabetes patients.
Data from ATLAS includes:
"Asian Treat to Target Lantus Study (ATLAS): a 24 week randomized,
multinational study"
Embargo lifts: Saturday, June 22, 10 am CST
Presenter: S. Garg, University of Colorado Health Sciences Center,
Denver, Colorado, USA
Location: Poster Hall
"Evaluating the patient experience in the Asian Treat to Target Lantus
Study (ATLAS): a 24-week randomized, multinational study"
Embargo lifts: Saturday, June 22, 10 am CST
Presenter: N. Freemantle, University College London, UK
Location: Poster Hall
BGStar(R)
Now available in 14 countries across four continents, our intuitive blood
glucose monitoring (BGM) devices BGStar(R) and iBGStar(R) form a key part of
our comprehensive patient-centric portfolio and are at the heart of our
integrated approach to diabetes.
Key BGStar(R) data show that the performance of our self-monitoring BGM
device achieves similar system accuracy as point of care testing systems for
professional use:
"Evaluating system accuracy of blood glucose monitoring systems for point
of care testing"
Embargo lifts: Saturday, June 22, 10 am CST
Presenter: G. Freckmann, Institut fuer Diabetes-Technologie
Forschungs- und Entwicklungsgesellschaft mbH an der
Universitat Ulm, Germany
Location: Poster Hall (also available as an ePoster on the ADA
website after 10 am, June 22)
Sanofi will host a conference call for the financial community during the
upcoming ADA 73rd Scientific Sessions. The call will include results from the
ongoing EDITION Phase III program for the company's investigational new insulin
U300 as well as a status update on the fixed-ratio combination of insulin
glargine and lixisenatide.
The conference call will take place on Monday June 24, 2013, at 7 am CST (2
pm CET). Dial-in numbers and the audio webcast link will be accessible via
About Diabetes
Diabetes is a chronic disease that occurs as type 1 diabetes, which is an
autoimmune disease characterized by the lack of insulin (the hormone that
regulates blood glucose concentrations) production by the pancreas, and type 2,
a metabolic disorder in which there are two main biological defects: a
deficient production of insulin and reduced ability of the body to respond to
the insulin being produced. Type 1 and type 2 diabetes are characterized by an
increase in blood glucose concentrations (hyperglycemia). Over time,
uncontrolled hyperglycemia leads to the macrovascular and microvascular
complications of diabetes. Macrovascular complications, which affect the large
blood vessels, include heart attack, stroke and peripheral vascular disease.
Microvascular
complications affect the small blood vessels of the eyes (retinopathy), kidney
(nephropathy) and nerves (neuropathy). The global incidence of diabetes is
growing at an alarming rate, with more than 371 million people worldwide living
with the condition today.[2]
About Sanofi Diabetes
Sanofi strives to help people manage the complex challenge of diabetes by
delivering innovative, integrated and personalized solutions. Driven by
valuable insights that come from listening to and engaging with people living
with diabetes, the Company is forming partnerships to offer diagnostics,
therapies, services and devices, including blood glucose monitoring systems.
Sanofi markets both injectable and oral medications for people with type 1 or
type 2 diabetes.
About Sanofi
Sanofi, an integrated global healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).
Footnote
*Lixisenatide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), was
in-licensed from Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL),
http://www.zealandpharma.com, and is approved in Europe, Mexico and Australia
for the treatment of patients with type 2 diabetes mellitus. Lyxumia is the
proprietary name approved by the EMA, Australia and Mexico, and submitted to
other health authorities for the GLP-1 RA lixisenatide. The proprietary name
for lixisenatide in the United States is under consideration.
References
1. Gerstein H (ORIGIN Trail Investigators) et al. Basal Insulin and
Cardiovascular and Other Outcomes in Dysglycemia. New England Journal of
Medicine 2012; 367: 319-328.
2. International Diabetes Federation. IDF Diabetes Atlas, 5th edition: 2012
update. Brussels, Belgium, 2011. http://www.idf.org/diabetesatlas (Accessed:
June, 2013)
Forward-Looking Statements
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include projections and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with respect to future
financial results, events, operations, services, product development and
potential, and statements regarding future performance. Forward-looking
statements are generally identified by the words "expects", "anticipates",
"believes", "intends", "estimates", "plans" and similar expressions. Although
Sanofi's management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally beyond the
control of Sanofi, that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and uncertainties
include among other things, the uncertainties inherent in research and
development, future clinical data
and analysis, including post marketing, decisions by regulatory authorities,
such as the FDA or the EMA, regarding whether and when to approve any drug,
device or biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other matters
that could affect the availability or commercial potential of such product
candidates, the absence of guarantee that the product candidates if approved
will be commercially successful, the future approval and commercial success of
therapeutic alternatives, the Group's ability to benefit from external growth
opportunities, trends in exchange rates and prevailing interest rates, the
impact of cost containment policies and subsequent changes thereto, the average
number of shares outstanding as well as those discussed or identified in the
public filings with the SEC and the AMF made by Sanofi, including those listed
under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking
Statements" in Sanofi's annual report on Form 20-F for the year ended December
31, 2012. Other than as required by applicable law, Sanofi does not undertake
any obligation to update or revise any forward-looking information or
statements.
SOURCE: Sanofi Diabetes
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
